Parkinsons Disease Drugs Market

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.

Parkinsons Disease Drugs Market contains market size and forecasts of Parkinson's Disease (PD) Drugs in global, including the following market information:

• Global Parkinson's Disease (PD) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Parkinson's Disease (PD) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
• Global top five Parkinson's Disease (PD) Drugs companies in 2021 (%)

The global Parkinson's Disease (PD) Drugs market was valued at 5651 million in 2021 and is projected to reach US$ 8374.4 million by 2028, at a CAGR of 5.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Dopamine Agonist Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Parkinson's Disease (PD) Drugs include Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen and Eisai, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Parkinson's Disease (PD) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Parkinson's Disease (PD) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Parkinson's Disease (PD) Drugs Market Segment Percentages, by Type, 2021 (%)

• Dopamine Agonist
• Monoamine Oxidase Inhibitors
• Acetylcholinesterase Inhibitors
• Glutamate Inhibitors

Global Parkinson's Disease (PD) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Parkinson's Disease (PD) Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Family

Global Parkinson's Disease (PD) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Parkinson's Disease (PD) Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Parkinson's Disease (PD) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Parkinson's Disease (PD) Drugs revenues share in global market, 2021 (%)
• Key companies Parkinson's Disease (PD) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
• Key companies Parkinson's Disease (PD) Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries
• AbbVie
• Abital Pharma
• Addex Therapeutics
• Biogen
• Eisai
• Eli Lilly
• F. Hoffmann-La Roche
• H. Lundbeck
• Impax Laboratories
• Kyowa Hakko Kirin
• Otsuka Pharmaceutical
• Pfizer